Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study

NCT07454473 is registered in ClinicalTrials.gov with Chuansheng Zhao as lead sponsor.

NCT NCT07454473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07454473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Edaravone and Dexborneol Sublingual Tablet for Treating Chemotherapy- Induced Cognitive Impairment Study
Lead sponsor
Chuansheng Zhao
Phase
Phase 4
Overall status
Recruiting
Start date
March 2, 2026
Completion date
December 31, 2027
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemo brain